NICE rejected Janssen’s Darzalex (Daratumumab) back in March last year, concluding that it wasn’t able to accurately determine the efficacy of the drug based on data submitted and therefore couldn’t reach a decision on cost-effectiveness.
Nearly one year later and a further appraisal on, NICE has reached the conclusion that it isn’t adequately able to determine the efficacy of the drug.
It will be some comfort to the company that NICE recommended that the drug be made available through the Cancer Drug Fund while it further evaluates the treatment.
